Navigation Links
Intrinsic Imaging Awarded Phase II Immuno-Oncology Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Date:3/22/2017

Intrinsic Imaging, LLC, an FDA audited and ISO certified medical imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that it has been awarded a multi-year phase II immuno-oncology clinical trial for the treatment of non-small cell lung cancer and small cell lung cancer.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including protocol and charter development, site qualification, site training and management, image transfer, quality control and processing. In addition, Intrinsic Imaging’s full-time board-certified, fellowship trained radiologists will also evaluate the patients’ tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criterion.

“Intrinsic Imaging was selected due to our extensive therapeutic experience and operational excellence in oncology and immuno-oncology clinical trials,” said Todd A. Joron, BSc., MBA, President & COO at Intrinsic Imaging. “With our team of 70 fellowship trained radiologists, robust and scalable clinical imaging technologies and our ISO certified quality management systems, Intrinsic Imaging is ideally positioned to provide our expertise in the assessment of non-small cell lung cancer and other lung cancers.”

Intrinsic Imaging's board-certified team includes 12 oncology focused radiologists with an extensive breadth of experience in clinical trials involving carcinomas, sarcomas, and lymphomas. The company also has significant expertise in a range of assessment criterion including , but not limited to, BIRADS, Cheson, irRECIST, Lugano, Macdonald, mRecist, PERCIST, RANO and RECIST.

Lung cancer is the leading cause of cancer death across the globe, claiming more lives than the next three most common cancers combined. Non-small cell lung cancer accounts for some 85% of lung cancer diagnoses. The five-year survival rate is low often due to most patients having advanced disease at the time of presentation. Intrinsic Imaging proudly lends its expertise on this clinical trial in an effort to help in the development of an effective treatment for lung cancer.

About Intrinsic Imaging, LLC
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001, ISO 13485, ISO 22301 and ISO 27001 certified and GAMP5 compliant medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than seventy full-time board-certified fellowship trained radiologists, robust and scalable clinical imaging technologies and its ISO certified quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world. For more information, please visit http://www.IntrinsicImaging.com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14170750.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Intrinsic Clinical Systems Unveils a New Kind of Clinical Trial Management System
2. New Intrinsically Safe XPP-5454GC LED Headlamp from Nightstick® Now Clips Direct to Hard Hats
3. Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight
4. Intrinsic Imaging Awarded Medical Device Trial for Percutaneous Tumor Ablation
5. RSNA: Noninvasive Imaging Helps Predict Heart Attacks
6. Functional Imaging Supports Improved Cognition in Parkinson’s Disease Patients After REHACOP
7. Canopy Partners Launches Canopy CARE – An End-To-End Referral Management Platform For Medical Imaging Providers
8. Scottsdale Medical Imaging Recognized with Award from the Southwest Alliance for Excellence.
9. Camellia Women’s Imaging Helping Diminish Breast Cancer Screening Anxiety
10. RSNA: Imaging Links Structural Brain Changes and Cognitive Decline in Parkinson’s
11. NIH Awards Nocturnal Product Development and GW a $2.27M Phase II STTR Grant for Preclinical Development of Cardiac Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... , ... August 20, 2017 , ... Are you an ... household? If so, you may be interested in participating in a research study ... this research is to understand more about the relational aspects of adults who have ...
(Date:8/19/2017)... ... August 18, 2017 , ... President Donald Trump ... legislation that provides for greater public access to over-the-counter (OTC) hearing aids. , ... OTC hearing aids without being seen by a certified and licensed audiologist. ...
(Date:8/19/2017)... CA (PRWEB) , ... August 19, 2017 , ... Yesterday, ... the KKK by saying there are two sides. There are not two sides to ... way to rationalize violence and prejudice, and the NPEIV stands against all forms of ...
(Date:8/18/2017)... (PRWEB) , ... August 19, 2017 , ... ... Tourism Authority of Thailand presided over the Amazing Thailand Health and Wellness Tourism ... Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business at ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , In ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... August 17, 2017 DarioHealth Corp. (NASDAQ: ... mobile health and big data solutions, announced today ... domestic and non-U.S. investors for the sale of ... of the Company,s newly designated Series B Convertible ... Company expects to conduct a closing with respect ...
(Date:8/15/2017)... WILMINGTON, N.C. , Aug. 15, 2017 ... Wilmington, NC , today announced that the company ... at the University of North Carolina at Chapel Hill ... AccuKit-HIV is designed to characterize and quantify HIV reservoir ... and after pharmacological intervention. The HIV Cure Center is ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
Breaking Medicine Technology: